Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?

Details

Serval ID
serval:BIB_8B1884CC3895
Type
Article: article from journal or magazin.
Collection
Publications
Title
Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
Journal
Annals of oncology
Author(s)
Petrausch U., Samaras P., Veit-Haibach P., Tschopp A., Soyka J.D., Knuth A., Hany T.F., Mischo A., Renner C., Schaefer N.G.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
05/2010
Peer-reviewed
Oui
Volume
21
Number
5
Pages
1053-1057
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
The purpose of the study was to evaluate the impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/computed tomography (CT) during follow-up of patients with Hodgkin's lymphoma.
Patients in complete remission or an unconfirmed complete remission after first-line therapy who received FDG-PET/CT during their follow-up were analyzed retrospectively. Confirmatory biopsy was mandatory in case of recurrence.
Overall, 134 patients were analyzed. Forty-two (31.3%) patients had a recurrence. The positive predictive value of FDG-PET/CT was 0.98. Single-factor analysis identified morphological residual mass [P = 0.0005, hazard ratio (HR) 3.4, 95% confidence interval (CI) 1.7-6.6] and symptoms (P < 0.0001, HR 4.9, 95% CI 2.4-9.9) as significant risk factors for relapse. By multivariate analysis, morphological residual mass was the only significant risk factor for early follow-up (<24 months) (P = 0.0019, HR 7.6, 95% CI 2.1-27.3). Advanced stage (P = 0.0426, HR 3.6, 95% CI 1.1-12.3) and the presence of symptoms (P = 0.0009, HR = 14.6, 95% CI 3.0-69.7) were found to be significant risk factors for later follow-up (>24 months).
Asymptomatic patients without morphological residues and an early stage of disease do not need a routine FDG-PET/CT for follow-up. Asymptomatic patients with morphological residues should receive routine follow-up FDG-PET/CT for the first 24 months. Only patients with advanced initial stage do need a routine follow-up FDG-PET/CT beyond 24 months.
Keywords
Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Female, Fluorodeoxyglucose F18, Follow-Up Studies, Hodgkin Disease/diagnostic imaging, Hodgkin Disease/drug therapy, Humans, Male, Middle Aged, Neoplasm Recurrence, Local/diagnosis, Neoplasm Staging, Positron-Emission Tomography/statistics & numerical data, Prognosis, Radiopharmaceuticals, Remission Induction, Retrospective Studies, Risk Factors, Survival Rate, Tomography, X-Ray Computed/statistics & numerical data
Pubmed
Web of science
Open Access
Yes
Create date
07/05/2019 10:20
Last modification date
30/08/2019 5:26
Usage data